How Colossal Biosciences resurrected the dire wolf using ancient DNA

Executive overview

Biodiversity loss is accelerating — up to 50% of species could vanish by 2050. Colossal Biosciences responds with functional de-extinction: using ancient genomes and modern gene-editing to rebuild lost species from their closest living relatives. The dire wolf was brought back not by cloning from preserved cells, but by editing 15 genes into gray wolf DNA using a 13,000-year-old tooth and a 72,000-year-old skull.

The business model pairs long-term conservation impact with near-term technology spin-outs. Conservation tools developed on the path to de-extinction are shared free with partners.

De-extinction and species preservation are the same mission, not competing ones.

How functional de-extinction works

• Extinct species can't be cloned — no living cells exist
• AI analysis of ancient genomes identifies which genes drove distinct physical traits
• Those genes are edited into the closest living relative (gray wolves for dire wolves)
• Embryos are created via somatic cell nuclear transfer and carried by domestic dogs
• Dire wolves turned out to be white — unknown before genome analysis

The science debate and Colossal's response

• Critics argue the animals are genetically modified wolves, not true dire wolves
• Ben Lamm's position: over 30 ways to classify a species; 95% of top scientists support the work
• Gray wolves are already 99.5% genetically identical to dire wolves
• Colossal's framing mirrors Jurassic Park — the science is the same, semantics is the debate
• Beth Shapiro, formerly a critic, is now Colossal's chief science officer

What's next in the pipeline

• Woolly mammoth: ~85 gene edits needed; 25 done; gestation challenge is 22 months
• Thylacine and dodo projects on track, some slightly ahead of schedule
• Red wolf: only 15 left in the wild; Colossal already cloned more red wolves than dire wolves
• New technique allows cloning from a blood draw — no anesthesia or skin biopsy needed
• Northern white rhino: exclusive genetic rescue partner, two females left

The business model

• No product revenue yet — "a giant R and a little D"
• Three spin-outs: Form Bio (computational biology platform, $100M+), Breaking (plastic-degrading biomass), and one unannounced ($100M+)
• Long-term revenue thesis: biodiversity credits and government subsidies for rewilded species
• $50M raised separately for the Colossal Foundation to fund external conservation research

Exogenous development and human implications

• Colossal is building artificial womb technology (exodev) for species like the northern white rhino
• Goal: grow 200 genetically diverse rhinos in a lab without involving any living rhino
• Technology could improve human IVF — embryo grading is seen as "moderately archaic"
• Colossal will not apply the technology to humans or non-human primates
• Spin-out model means other teams with different mandates could pursue human applications

Ethics and Colossal's framework

• Colossal built its own ethical guidelines rather than waiting for external ones
• No work on non-human primates, neanderthals, or species without a conservation tie-back
• Lamm's view: humans "play God" every time they overfish, deforest, or eradicate a species
• Response to "playing God" critics: a moral obligation exists given the scale of biodiversity loss
• Welcomes a thousand competitors — de-extinction alone cannot solve the extinction crisis